Identiﬁcation of CD114 Membrane Receptors as a Molecular Target in Medulloblastomas

Sep 24, 2026

Uploaded by Finn

Medulloblastomas are the most common solid pediatric brain tumors, forming 8–30% of pediatric brain cancers, and they often show high-grade, aggressive behavior with a typically poor prognosis. The disease differs across four molecular subgroups (WNT, SHH, Group 3, and Group 4), and treatment combining surgery, chemotherapy, and radiotherapy is associated with considerable morbidity. This study analyzed MAGIC consortium databases to evaluate CD114 membrane receptor expression by molecular type and its relationship with mortality, finding subgroup-specific CD114 differences but no statistically significant association between low vs high CD114 expression and death, suggesting no direct prognostic link in these patients.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages12

Reading Time30 min

AccessFree to download

Introduction

Background and disease classification

Treatment and prognosis risk stratification

Rationale for molecular targeted approaches

Study design and analysis

MAGIC consortium database analysis

CD114 expression across molecular groups

Association with mortality

Article Identiﬁcation of CD114 Membrane Receptors as a Molecular Target in Medulloblastomas Jander Moreira Monteiro 1,2, Jaqueline Isadora Reis Ramos 3, Ian Teixeira e Sousa 4, Rayana Longo Bighetti-Trevisan 3, Jurandir Marcondes Ribas Filho 2 and Gustavo Rassier Isolan 1,2, * Citation: Monteiro, J.M.; Reis Ramos, J.I.; Teixeira e Sousa, I.; Bighetti-Trevisan, R.L.; Ribas Filho, J.M.; Isolan, G.R. Identiﬁcation of CD114 Membrane Receptors as a Molecular Target in Medulloblastomas. Int. J. Mol. Sci. 2023, 24, 5331. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms24065331](10.3390/ijms24065331) Academic Editor: Peter Hau Received: 30 January 2023 Revised: 4 March 2023 Accepted: 5 March 2023 Published: 10 March 2023 Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) . 1 Department of Neurosurgery, Center for Advanced Neurology and Neurosurgery (CEANNE), Porto Alegre 90560-010, Brazil 2 Postgraduate Program, Mackenzie Evangelical College of Parana, Curitiba 81531-980, Brazil 3 School of Dentistry of Ribeirao Preto, University of Sao Paulo, Ribeir¢o Preto 14040-904, Brazil 4 Pediatric Intensive Care Unit, Conceiç¢o Children's Hospital, Porto Alegre 90560-010, Brazil * Correspondence: [gisolan@yahoo.com.br](gisolan@yahoo.com.br) Abstract: Medulloblastomas are the most common solid tumors in children, accounting for 8–30% of pediatric brain cancers. It is a high-grade tumor with aggressive behavior and a typically b poor prognosis. Its treatment includes surgery, chemotherapy, and radiotherapy, and presents high morbidity. Signiﬁcant clinical, genetic, and prognostic differences exist between its four molecular subgroups: WNT, SHH, Group 3, and Group 4 . Many studies seek to develop new chemotherapeutic agents for medulloblastomas through the identiﬁcation of genes whose expressions are new molecular targets for drugs, such as membrane receptors associated with cell replication. This study aimed to assess the association of CD114 expression with mortality in patients with medulloblastoma. Databases from the Medulloblastoma Advanced Genomics International Consortium (MAGIC) were analyzed, focusing on the expression of the CD114 membrane receptor in different molecular types and its possible association with mortality. Our ﬁndings showed different CD114 expressions between Group 3 and other molecular groups, as well as between the molecular subtypes SHH 􀀍 and Group 3 􀀋 and Group 3 􀀌 . There was no statistically signiﬁcant difference between the other groups and subtypes. Regarding mortality, this study did not ﬁnd statistical signiﬁcance in the association between low and high CD114 expressions and mortality. Medulloblastoma is a heterogeneous disease with many subtype variations of its genetic and intracellular signaling pathways. Similarly to this study, which could not demonstrate different CD114 membrane receptor expression patterns between groups, others who sought to associate CD114 expression with mortality in other types of cancer failed to establish a direct association. Since many indications point to the relation of this gene with cancer stem cells (CSCs), it may be part of a more extensive cellular signaling pathway with an eventual association with tumor recurrence. This study found no direct relationship between CD114 expression and mortality in patients with medulloblastoma. Further studies are needed on the intracellular signaling pathways associated with this receptor and its gene (the CSF3R) . Keywords: neurosurgery; surgical oncology; molecular targeted therapy; medulloblastoma 1. Introduction Medulloblastomas are the most common solid tumors in children, a

FAQs

What was the main objective of the study on CD114 in medulloblastoma?

To assess whether CD114 expression is associated with mortality in patients with medulloblastoma by analyzing its expression across molecular subgroups.

How were CD114 expression levels compared among medulloblastoma molecular groups?

The study analyzed MAGIC consortium databases, focusing on CD114 membrane receptor expression across different molecular types and subtypes.

Did CD114 expression correlate with mortality in medulloblastoma patients?

No. The study did not find a statistically significant association between low and high CD114 expression and mortality.

Sep 24, 2026

Uploaded by Finn